SeHCAT improves confidence of treatment selected
SeHCAT test gives an objective diagnosis of BAD enabling clinicians to confidently treat with bile acid sequestrant.1,2
Bile acid sequestrants (BAS) such as cholestyramine have been shown to be effective in treating diarrhoea secondary to bile acid malabsorption, with up to 96% of D-IBS patients diagnosed with BAM responding.3
Therapeutic options for Bile Acid Diarrhoea
- Cholestyramine is typically used first-line to treat people diagnosed with BAD. Approximately 50% of people prescribed cholestyramine will continue with this treatment long term.4
- For those who cannot tolerate cholestyramine, some gastroenterologists treat BAD with newer BAS treatments, like colesevelam. It is typically better tolerated4, however, this use is not licensed in the UK yet.
- Modification of diet has been also suggested as a treatment option, especially for patients with BAD after cancer therapy. The fat reduction can improve symptoms, making it an important therapeutical option.5
1. Smith MJ et al. J R Coll Physicians Lond 2000; 34 (5): 448-51.
2. Basumani et al. Gut 2008; 57 (Suppl I): A1-A172.
3. Wedlake L et al. Aliment Pharmacol Ther 2009; 30 (7): 707-17.
4. NICE diagnostics guidance [DG7] 2012.
5. Gupta A et al. Support Care Cancer 2015 1-10.